Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$4.00
+0.3%
$2.85
$0.72
$6.24
$257.60M2.29896,651 shs386,435 shs
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
$0.03
$0.07
$1.09
$30.20M2.422.59 million shs65.74 million shs
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
$0.05
+44,900.0%
$0.01
$0.00
$0.50
$5.70M-23.154,528 shs5,325 shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$9.00
+0.4%
$9.00
$8.15
$22.40
$249.51M2.1196,079 shs95,330 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
+0.25%+0.50%+1.27%+334.78%-9.50%
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
0.00%0.00%0.00%0.00%0.00%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
+44,900.00%+350.00%+44,900.00%+800.00%-86.80%
ZimVie Inc. stock logo
ZIMV
ZimVie
+0.45%+4.53%+2.51%-17.51%-50.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
3.2199 of 5 stars
4.23.00.00.02.62.50.0
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
N/AN/AN/AN/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
2.899 of 5 stars
3.35.00.00.01.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.44
Hold$11.75193.75% Upside
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
0.00
N/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
0.00
N/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
2.67
Moderate Buy$16.3381.48% Upside

Current Analyst Ratings Breakdown

Latest ZIMV, SDC, VAXX, and INZY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$4.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$15.00 ➝ $4.00
5/15/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $10.00
5/14/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
4/10/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/10/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$16.00
4/9/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/9/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$0.90 per shareN/A
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
$414.88M0.00N/AN/A($0.99) per share0.00
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/A$0.11 per shareN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
$449.75M0.56$1.87 per share4.82$13.83 per share0.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
-$86.40M-$0.65N/AN/AN/A-19.94%N/A-14.55%N/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
-$56.93M-$0.45N/AN/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
-$25.83M-$0.71N/AN/A-4.40%5.53%2.84%7/31/2025 (Estimated)

Latest ZIMV, SDC, VAXX, and INZY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
5/8/2025Q1 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.21$0.27+$0.06-$0.05$113.10 million$112.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
N/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.65
2.19
2.19
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
N/A
1.90
1.58
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
0.58
2.14
1.48

Institutional Ownership

CompanyInstitutional Ownership
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
4.32%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
82.95%
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
12.18%
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
64.70%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
64.06%
ZimVie Inc. stock logo
ZIMV
ZimVie
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million56.70 millionOptionable
SmileDirectClub, Inc. stock logo
SDC
SmileDirectClub
2,700402.61 million142.12 millionNot Optionable
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
90126.75 million45.55 millionNot Optionable
ZimVie Inc. stock logo
ZIMV
ZimVie
1,77027.85 million27.01 millionOptionable

Recent News About These Companies

ZimVie: Screening Cheap (Rating Upgrade)
ZimVie Inc. (ZIMV) Q1 2025 Earnings Call Transcript
ZimVie Reports First Quarter 2025 Financial Results
Q1 2025 ZimVie Inc Earnings Call
ZimVie announces launch of its Immediate Molar Implant system in US
ZimVie launches molar implant system
Needham Remains a Hold on ZimVie Inc (ZIMV)
ZimVie initiated with a Buy at B. Riley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$4.00 +0.01 (+0.25%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$4.00 0.00 (-0.12%)
As of 06/26/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

SmileDirectClub stock logo

SmileDirectClub NASDAQ:SDC

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

Vaxxinity stock logo

Vaxxinity NASDAQ:VAXX

$0.04 +0.04 (+44,900.00%)
As of 06/26/2025 09:51 AM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

ZimVie stock logo

ZimVie NASDAQ:ZIMV

$9.00 +0.04 (+0.45%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$9.40 +0.40 (+4.44%)
As of 06/26/2025 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.